Pirh2 Antibody (YA5020)
(Synonyms: RCHY1; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; RING finger and CHY zinc finger domain-containing protein 1; Androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger)Pirh2 Antibody (YA5020) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Pirh2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB; ICC/IF; IP
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IP
IP: Immunoprecipitation
|
|---|---|---|---|
| Dilution Ratio | 1:500-2000 | 1:50-200 | 1:20-50 |
Product Details
Pirh2 Antibody (YA5020) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Pirh2.
-
Host Rabbit
-
Clonality Monoclonal, Recombinant
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 30 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 30 kDa
A synthesized peptide derived from human RCHY1. The exact sequence is proprietary to MCE.
Endogenous
affinity purified by Protein A
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Pirh2 is an E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B. Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53. Catalyzes monoubiquitinates the translesion DNA polymerase POLH. Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation; Has no E3 ubiquitin-protein ligase activity[1][2][3][4][5][6][7][8].
-
Subcellular Localization
Nucleus; Nucleus speckle; Cytoplasm
-
Expression
Induction:Up-regulated during the S phase of the cell cycle (PubMed:18006823) . Expressed at low levels during G phase (PubMed:18006823) ; Down-regulated in hepatocellular carcinoma -
Isoforms & Post-Translational Modification
Q96PM5 has 8 isomers: Q96PM5-1: 30110 Da (predicted); Q96PM5-2: 28983 Da (predicted); Q96PM5-3: 20720 Da (predicted); Q96PM5-4: 21697 Da (predicted); Q96PM5-5: 8494 Da (predicted); Q96PM5-6: 27676 Da (predicted); Q96PM5-7: 25337 Da (predicted); Q96PM5-8: 24210 Da (predicted).
Subject to ubiquitination and proteasomal degradation. Interaction with PLAGL2 or KAT5 enhances protein stability -
Subunit
Monomer and homodimer. Interacts with AR, MDM2, KAT5, PLAG1, PLAGL2, COPE, UBE2D2 and GORAB/NTKLBP1
-
SwissProt ID
-
Synonyms
RCHY1; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; RING finger and CHY zinc finger domain-containing protein 1; Androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger
Documentation
Powered by Bioz
